Equity Profile

PFE

Pfizer Inc.

Health CarePharmaceuticals$148.0B

May5Tue

Post-Earnings Recap

ReportedQ1-2026Pre-Market6:45 AM EDT

Pfizer Beats on EPS, Stock Up 0.57%

Metric	Actual	Expected	Surprise
EPS	$0.75	$0.72	+5.63%
Revenue	N/A	$13.8B	N/A

management commentary, guidance changes, and full analysis available with Pro.

Pfizer Beats on EPS, Stock Up 0.57%

Key Numbers

Metric	Actual	Expected	Surprise
EPS	$0.75	$0.72	+5.63%
Revenue	N/A	$13.8B	N/A

Management Commentary

Tone: Unknown

No transcript is on record for the earnings call, so analysis is based solely on numerical results.

What It Means

Pfizer's earnings report shows a positive surprise in EPS, which likely contributed to the stock's modest increase of 0.57%. However, the lack of revenue data and management commentary leaves some uncertainty about the company's overall performance and future outlook.

Company Snapshot

Pfizer Inc. is a leading pharmaceutical company known for developing and manufacturing medicines and vaccines....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and helps investors gauge the company's financial health.

$0.72

Revenue

Revenue figures provide insight into the company's sales performance and market demand for its products.

$13.8B

Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Pfizer Inc. is a leading pharmaceutical company known for developing and manufacturing medicines and vaccines. With a market cap of $150 billion, it plays a crucial role in the health care sector, especially in the wake of the COVID-19 pandemic and ongoing health challenges.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+33.22%

Avg Stock Reaction

+0.46%

Last Quarter Recap

In Q4 2025, Pfizer reported an EPS of $0.66, exceeding expectations by 16.81%. However, the stock fell 3.34% the following day, indicating market caution despite the earnings beat.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect Pfizer to report solid earnings, with a consensus EPS of $0.72 and revenue of $13.8 billion. The market is closely watching how the company navigates post-COVID dynamics.

Bull Case

If Pfizer exceeds EPS expectations, it could signal strong demand for its products and a recovery in its core business, potentially boosting investor confidence.

Bear Case

Conversely, if the company misses earnings expectations or provides weak guidance, it could raise concerns about its growth trajectory and market position.

Key Metrics to Watch

EPS

$0.72

Earnings per share is a key indicator of profitability and helps investors gauge the company's financial health.

Revenue

$13.8B

Revenue figures provide insight into the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Pfizer's EPS exceed the consensus estimate of $0.72?

A beat on EPS could indicate stronger-than-expected demand for its products and boost investor confidence.

What guidance will management provide regarding future revenue growth?

Future revenue guidance is crucial for assessing the company's growth trajectory and market outlook.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate the impact of new product launches and ongoing demand for vaccines, which could drive stronger revenue than expected.

Supporting Evidence

Pfizer has consistently beaten EPS estimates in recent quarters, indicating strong operational performance.

The options market is pricing a 4.2% move, suggesting expectations of volatility that may not align with actual performance.

Key Risk

If new product sales significantly exceed expectations, it could challenge the current consensus view.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is critical as it reflects Pfizer's ability to sustain growth post-COVID and adapt to changing market conditions.

Bull Confirmed If

An EPS of $0.75 or higher would confirm strong demand and positive market sentiment.

Bear Confirmed If

An EPS below $0.68 would raise concerns about the company's growth and market position.

Pre-Earnings Positioning

Options Market

Implied Move

±4.2%

Historical Avg

±2.3%

Pricing rich

The options market is pricing in a significant move, suggesting that investors expect volatility around the earnings announcement.

Options are pricing ±4.5% while PFE has averaged ±2.3% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

21.0%

Calls (11.5M)P/C Ratio: 0.43Puts (5.0M)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Pfizer beats expectations, history suggests the stock could rise by around 1.15%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may see muted movement as investors await further guidance.

Miss

If Pfizer misses earnings expectations, history suggests a potential decline of about 3.01%, raising concerns about its growth.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

1 buy·3 sells

Members

House only

Est. Notional

$103,004.00–$295,000.00

disclosed dollar ranges

Most Active Members

D-CAGilbert CisnerosRep.
3

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any commentary on vaccine demand and sales trends.
2Updates on new product launches and their expected impact on revenue.
3Management's outlook on market conditions and competitive landscape.
4Insights into cost management and operational efficiency.
5Guidance on future earnings and revenue expectations.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

May4

GRABReported

Grab Holdings Limited

RecapView

May4

GBDCReported

Company Snapshot

Pfizer Inc. is a leading pharmaceutical company known for developing and manufacturing medicines and vaccines....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and helps investors gauge the company's financial health.

$0.72

Revenue

Revenue figures provide insight into the company's sales performance and market demand for its products.

$13.8B

Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+33.22%

Avg Stock Reaction

+0.46%

Last Quarter Recap

In Q4 2025, Pfizer reported an EPS of $0.66, exceeding expectations by 16.81%. However, the stock fell 3.34% the following day, indicating market caution despite the earnings beat.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect Pfizer to report solid earnings, with a consensus EPS of $0.72 and revenue of $13.8 billion. The market is closely watching how the company navigates post-COVID dynamics.

Bull Case

If Pfizer exceeds EPS expectations, it could signal strong demand for its products and a recovery in its core business, potentially boosting investor confidence.

Bear Case

Conversely, if the company misses earnings expectations or provides weak guidance, it could raise concerns about its growth trajectory and market position.

Key Metrics to Watch

EPS

$0.72

Earnings per share is a key indicator of profitability and helps investors gauge the company's financial health.

Revenue

$13.8B

Revenue figures provide insight into the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Pfizer's EPS exceed the consensus estimate of $0.72?

A beat on EPS could indicate stronger-than-expected demand for its products and boost investor confidence.

What guidance will management provide regarding future revenue growth?

Future revenue guidance is crucial for assessing the company's growth trajectory and market outlook.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate the impact of new product launches and ongoing demand for vaccines, which could drive stronger revenue than expected.

Supporting Evidence

Pfizer has consistently beaten EPS estimates in recent quarters, indicating strong operational performance.

The options market is pricing a 4.2% move, suggesting expectations of volatility that may not align with actual performance.

Key Risk

If new product sales significantly exceed expectations, it could challenge the current consensus view.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is critical as it reflects Pfizer's ability to sustain growth post-COVID and adapt to changing market conditions.

Bull Confirmed If

An EPS of $0.75 or higher would confirm strong demand and positive market sentiment.

Bear Confirmed If

An EPS below $0.68 would raise concerns about the company's growth and market position.

Pre-Earnings Positioning

Options Market

Implied Move

±4.2%

Historical Avg

±2.3%

Pricing rich

The options market is pricing in a significant move, suggesting that investors expect volatility around the earnings announcement.

Options are pricing ±4.5% while PFE has averaged ±2.3% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

21.0%

Calls (11.5M)P/C Ratio: 0.43Puts (5.0M)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Pfizer beats expectations, history suggests the stock could rise by around 1.15%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may see muted movement as investors await further guidance.

Miss

If Pfizer misses earnings expectations, history suggests a potential decline of about 3.01%, raising concerns about its growth.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

1 buy·3 sells

Members

House only

Est. Notional

$103,004.00–$295,000.00

disclosed dollar ranges

Most Active Members

D-CAGilbert CisnerosRep.
3

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any commentary on vaccine demand and sales trends.
2Updates on new product launches and their expected impact on revenue.
3Management's outlook on market conditions and competitive landscape.
4Insights into cost management and operational efficiency.
5Guidance on future earnings and revenue expectations.